

David Webb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7542302/publications.pdf>

Version: 2024-02-01

134
papers

11,612
citations

43973

48
h-index

28224

105
g-index

139
all docs

139
docs citations

139
times ranked

12521
citing authors

#	ARTICLE	IF	CITATIONS
1	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. Journal of the American College of Cardiology, 2014, 63, 636-646.	1.2	1,446
2	The influence of heart rate on augmentation index and central arterial pressure in humans. Journal of Physiology, 2000, 525, 263-270.	1.3	913
3	Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, The, 2015, 386, 2059-2068.	6.3	904
4	Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, The, 1994, 344, 852-854.	6.3	577
5	Endothelin. Pharmacological Reviews, 2016, 68, 357-418.	7.1	574
6	Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology, 2011, 54, 1767-1776.	3.6	464
7	Measuring Forearm Blood Flow and Interpreting the Responses to Drugs and Mediators. Hypertension, 1995, 25, 918-923.	1.3	304
8	Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. British Journal of Clinical Pharmacology, 2001, 52, 631-646.	1.1	271
9	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. Circulation, 1996, 93, 1860-1870.	1.6	257
10	Endothelial Nitric Oxide Production and Insulin Sensitivity. Circulation, 1996, 93, 1331-1333.	1.6	254
11	Endothelin ET _A and ET _B Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation, 1995, 92, 357-363.	1.6	229
12	The Endothelin System and Its Antagonism in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 943-955.	3.0	216
13	The Endothelin Family of Peptides: Local Hormones with Diverse Roles in Health and Disease?. Clinical Science, 1993, 84, 485-500.	1.8	213
14	Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes and Endocrinology, the, 2018, 6, 464-475.	5.5	206
15	Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet, The, 2014, 383, 697-704.	6.3	172
16	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. Circulation, 1998, 97, 2323-2330.	1.6	158
17	Endothelins in cardiovascular biology and therapeutics. Nature Reviews Cardiology, 2019, 16, 491-502.	6.1	154
18	The endothelin system and its potential as a therapeutic target in cardiovascular disease. , 1996, 72, 109-148.		151

#	ARTICLE	IF	CITATIONS
19	Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. <i>Journal of Physiology</i> , 2001, 530, 541-550.	1.3	151
20	Prevalence and Causes of Prescribing Errors: The Prescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) Study. <i>PLoS ONE</i> , 2014, 9, e79802.	1.1	147
21	Long-term adverse effects of paracetamol – a review. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2218-2230.	1.1	145
22	Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease. <i>Hypertension</i> , 2011, 57, 772-779.	1.3	138
23	Seasonal Variation in Glucocorticoid Activity in Healthy Men ^{>1</sup>. <i>Journal of Clinical Endocrinology and Metabolism</i>, 1997, 82, 4015-4019.}	1.8	132
24	Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 545-550.	1.1	123
25	Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease. <i>Hypertension</i> , 2009, 54, 113-119.	1.3	113
26	Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 136-147.	5.5	99
27	Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. <i>British Journal of Pharmacology</i> , 1997, 120, 1376-1382.	2.7	93
28	Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. <i>BMJ: British Medical Journal</i> , 1998, 316, 834-837.	2.4	92
29	11 β -Hydroxysteroid Dehydrogenase Type 2 Deficiency Accelerates Atherogenesis and Causes Proinflammatory Changes in the Endothelium in ApoE ^{-/-} Mice. <i>Endocrinology</i> , 2011, 152, 236-246.	1.4	89
30	Direct Action of Endothelin-1 on Podocytes Promotes Diabetic Glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1050-1062.	3.0	87
31	Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. <i>British Journal of Cancer</i> , 2005, 92, 2148-2152.	2.9	82
32	An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1242-1248.	1.8	80
33	Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. <i>British Journal of Pharmacology</i> , 2001, 134, 648-654.	2.7	74
34	Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	74
35	The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons. <i>Kidney International</i> , 2020, 98, 323-342.	2.6	72
36	The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine. <i>Drugs</i> , 1996, 51, 12-27.	4.9	70

#	ARTICLE	IF	CITATIONS
37	Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease. <i>Journal of Lipid Research</i> , 2015, 56, 413-422.	2.0	70
38	Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. <i>JCI Insight</i> , 2016, 1, e89173.	2.3	70
39	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020, 177, 5467-5488.	2.7	65
40	Endothelin signalling mediates experience-dependent myelination in the CNS. <i>ELife</i> , 2019, 8, .	2.8	64
41	The increase in human plasma immunoreactive endothelin but not big endothelin or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. <i>British Journal of Pharmacology</i> , 1996, 119, 311-314.	2.7	62
42	Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. <i>Kidney International</i> , 2016, 89, 1125-1135.	2.6	62
43	Endothelin: from molecule to man. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 9-20.	1.1	60
44	Endothelium-Dependent Modulation of Responses to Endothelin-1 in Human Veins. <i>Clinical Science</i> , 1993, 84, 427-433.	1.8	59
45	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , 2016, 6, e010313.	0.8	58
46	Endothelial Dysfunction and Hypertension. <i>Drugs</i> , 1997, 53, 30-41.	4.9	57
47	S-Nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. <i>British Journal of Pharmacology</i> , 2000, 131, 1236-1244.	2.7	54
48	Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH ₂ -terminal 20 peptide (PAMP). <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 159-164.	1.1	52
49	Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development. <i>Cell Stem Cell</i> , 2020, 27, 822-839.e8.	5.2	51
50	Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7343 UK final-year medical students. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2249-2258.	1.1	50
51	Phosphoramidon inhibition of the <i>in vivo</i> conversion of big endothelin to endothelin in the human forearm. <i>British Journal of Pharmacology</i> , 1995, 116, 1821-1828.	2.7	47
52	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3228-3234.	0.4	47
53	Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. <i>Hepatology</i> , 2001, 33, 826-831.	3.6	45
54	Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose. <i>EClinicalMedicine</i> , 2019, 11, 11-17.	3.2	44

#	ARTICLE	IF	CITATIONS
55	Prescribing safety: ensuring that new graduates are prepared. <i>Lancet, The</i> , 2015, 385, 579-581.	6.3	39
56	Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. <i>Heart</i> , 2007, 93, 2-4.	1.2	37
57	Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 336-344.	1.1	36
58	A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1396-1405.	1.1	36
59	Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. <i>British Journal of Clinical Pharmacology</i> , 1997, 43, 493-499.	1.1	35
60	Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. <i>Circulation</i> , 2022, 145, 416-423.	1.6	35
61	Endothelin-A Receptor Antagonism Modifies Cardiovascular Risk Factors in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 31-36.	3.0	33
62	Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 521-527.	0.3	33
63	Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro : implications for anti-thrombotic therapy. <i>British Journal of Pharmacology</i> , 2000, 131, 1391-1398.	2.7	31
64	Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals. <i>Clinical Toxicology</i> , 2016, 54, 53-55.	0.8	31
65	A novel role for myeloid endothelin-B receptors in hypertension. <i>European Heart Journal</i> , 2019, 40, 768-784.	1.0	31
66	Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations. <i>Archives of Disease in Childhood</i> , 2015, 100, 662-666.	1.0	28
67	Imaging of cardiovascular risk in patients with Turner's syndrome. <i>Clinical Radiology</i> , 2015, 70, 803-814.	0.5	28
68	Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty. <i>Circulation</i> , 2000, 102, 1937-1943.	1.6	27
69	Clinical Experience With Endothelin Antagonists. <i>American Journal of Hypertension</i> , 1998, 11, 71S-79S.	1.0	25
70	New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 34.	1.5	25
71	Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 507-513.	1.1	22
72	Short-term effects of transdermal nicotine on acute tissue plasminogen activator release in vivo in man. <i>Cardiovascular Research</i> , 2001, 52, 321-327.	1.8	22

#	ARTICLE	IF	CITATIONS
73	Sildenafil improves renal function in patients with pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 235-241.	1.1	22
74	DORADO: Opportunity Postponed. <i>Hypertension</i> , 2010, 56, 806-807.	1.3	21
75	Endothelins come of age. <i>Lancet, The</i> , 1993, 342, 1439-1440.	6.3	20
76	Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 991-1028.	1.2	20
77	Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model. <i>Toxicological Sciences</i> , 2017, 159, 380-391.	1.4	19
78	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I. <i>Journal of Hypertension</i> , 2018, 36, 451-461.	0.3	19
79	Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 456-465.	1.0	19
80	Gastrin-releasing peptide is a potent vasodilator in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 252-259.	2.3	18
81	Therapeutic potential of endothelin receptor antagonism in kidney disease. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R388-R397.	0.9	18
82	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020, 41, 1606-1607.	1.0	18
83	Value-based medicine pricing: NICE work?. <i>Lancet, The</i> , 2011, 377, 1552-1553.	6.3	16
84	Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism. <i>Journal of the American Heart Association</i> , 2015, 4, e001624.	1.6	16
85	Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase) Tj ETQq1 1 0.784314 rgBT /Over 1.3 16	1.3	16
86	Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. <i>IScience</i> , 2021, 24, 101937.	1.9	16
87	Venous endothelin receptor function in patients with chronic heart failure. <i>Clinical Science</i> , 2000, 98, 65-70.	1.8	15
88	Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: Upregulation of smooth muscle ETB receptors that modulate contraction. <i>British Journal of Pharmacology</i> , 2000, 130, 1735-1744.	2.7	15
89	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1907-1924.	1.1	15
90	A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 75-81.	2.3	14

#	ARTICLE	IF	CITATIONS
91	Greater Functional ET _B Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy Men. <i>Hypertension</i> , 2010, 55, 1406-1411.	1.3	14
92	Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes. <i>Diabetologia</i> , 2017, 60, 1400-1408.	2.9	14
93	Improving medication safety: focus on prescribers and systems. <i>Lancet, The</i> , 2019, 394, 283-285.	6.3	14
94	Endogenous endothelin generation maintains vascular tone in humans. <i>Journal of Human Hypertension</i> , 1995, 9, 459-63.	1.0	14
95	Endothelin in Nondiabetic Chronic Kidney Disease: Preclinical and Clinical Studies. <i>Seminars in Nephrology</i> , 2015, 35, 176-187.	0.6	13
96	Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. <i>BMJ Open</i> , 2015, 5, e008951.	0.8	13
97	Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II. <i>Journal of Hypertension</i> , 2018, 36, 462-471.	0.3	13
98	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€œLed Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€œGlucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQqO O O TgBT /Overlock 10	4.3	13
99	Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. <i>Hypertension</i> , 2017, 69, 275-285.	1.3	12
100	Retinal fingerprints for precision profiling of cardiovascular risk. <i>Nature Reviews Cardiology</i> , 2019, 16, 379-381.	6.1	12
101	Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin S6c, in human resistance and capacitance vessels in vivo. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 27-30.	1.1	11
102	Reduced venous responsiveness to endothelinâ€œ1 but not noradrenaline in hypertensive chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 295-301.	0.4	10
103	Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: FigureÂ1. <i>BMJ Open</i> , 2015, 5, e007645.	0.8	10
104	Glucagon-Like PeptideÂ1 Receptor Agonist (GLP1RA) Exposure and Outcomes in TypeÂ2 Diabetes: A Systematic Review of Population-Based Observational Studies. <i>Diabetes Therapy</i> , 2021, 12, 969-989.	1.2	9
105	Endothelin Receptor Antagonists. <i>Drugs in R and D</i> , 1999, 2, 1-12.	1.1	8
106	Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury. <i>Kidney International</i> , 2020, 98, 1193-1209.	2.6	8
107	Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension. <i>BMJ Open</i> , 2015, 5, e008086.	0.8	7
108	First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis. <i>Hypertension</i> , 2017, 70, 192-200.	1.3	7

#	ARTICLE	IF	CITATIONS
109	Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD). <i>American Journal of Hypertension</i> , 2021, 34, 92-99.	1.0	7
110	The Role of Endothelin-1 in Cardiovascular Physiology and Pathophysiology. <i>Scottish Medical Journal</i> , 1995, 40, 69-71.	0.7	6
111	The endothelin system:a novel therapeutic target in cardiovascular disease. <i>Expert Opinion on Emerging Drugs</i> , 1998, 3, 95-112.	1.1	6
112	Arterial stiffness & Sri Lankan chronic kidney disease of unknown origin. <i>Scientific Reports</i> , 2016, 6, 32599.	1.6	6
113	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.	1.1	6
114	Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. <i>British Journal of Clinical Pharmacology</i> , 1993, 36, 293-301.	1.1	3
115	Endogenous angiotensin II does not contribute to sympathetic vasoconstriction in dorsal hand veins of healthy humans. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 327-333.	2.3	3
116	Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. <i>Clinical Science</i> , 2002, 103, 298S-301S.	1.8	3
117	Reply to J Rood and SR Smith. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 249-250.	2.2	3
118	Generation and 3-Dimensional Quantitation of Arterial Lesions in Mice Using Optical Projection Tomography. <i>Journal of Visualized Experiments</i> , 2015, , e50627.	0.2	3
119	A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2339-2342.	1.1	3
120	Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease. <i>Kidney International</i> , 2018, 93, 270.	2.6	3
121	Targeting Blood Vessel Stiffness to Protect Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2107-2109.	2.2	2
122	The acute pressure natriuresis response is suppressed by selective ETA receptor blockade. <i>Clinical Science</i> , 2021, , .	1.8	2
123	Research methods in human cardiovascular pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 395-395.	1.1	1
124	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 67-74.	2.3	1
125	Renal denervation therapy for hypertension: still on trial. <i>Heart</i> , 2019, 105, 1452-1453.	1.2	1
126	Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 375-377.	0.4	1

#	ARTICLE	IF	CITATIONS
127	The Clinical Section of the British Pharmacological Society: prospects for the future. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 215-218.	1.1	0
128	ACE inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 337-337.	1.1	0
129	A Comparison of the Haemodynamic Effects Pentaerythritol Tetranitrate and Isosorbide Mononitrate in Healthy Men. <i>Clinical Science</i> , 2003, 104, 16P-16P.	0.0	0
130	011.â€fCHORIORETINAL THICKNESS TRACKS DISEASE ACTIVITY IN CLINICAL ANCA VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
131	Urotensin receptor in GtoPdb v.2021.3. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	0
132	Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
133	Endothelin and blood pressure regulation. <i>Journal of Human Hypertension</i> , 1996, 10, 383-6.	1.0	0
134	Budget impact analysis of a pilot polypharmacy clinic. <i>British Journal of Health Care Management</i> , 2022, 28, 1-9.	0.1	0